Play TheStreet's FDA Drug Approval Contest

BOSTON (TheStreet) -- Let's add to the summer fun with a spur-of-the-moment FDA Drug Approval Contest.

Those who have participated in the past know the drill: Your challenge is to correctly predict the outcome of key FDA regulatory events. For this summer contest, the focus will be on four drug approval decisions and one advisory panel.

Here they are:

1. Onyx Pharmaceuticals (ONXX): FDA advisory panel for the cancer drug carfilzomib on June 20.

2. Arena Pharmaceuticals (ARNA): FDA approval decision for the weight-loss drug lorcaserin on June 27.

3. Vivus (VVUS): FDA approval decision for the weight-loss drug Qnexa on July 20.

4. Amarin (AMRN): FDA approval decision for the prescription fish-oil pill AMR101 on July 26.

5. Onyx (again): FDA approval decision for carfilzomib on July 27.

You have three outcomes to choose from for each drug-approval decision:

1. Full Approval: The big win, meaning the drug is approved and can be marketed for sale immediately.

2. Complete Response Letter (CRL): The FDA has some concerns or issues (incomplete data, labeling, risk management, etc.) that prevent the drug from being approved immediately. In other words, the drug's approval is rejected or delayed for some reason.

3. No Decision: The FDA chooses to extend the drug's review time, i.e., pushes out the approval decision to a later date.

For the Onyx FDA panel on June 20, predict whether the vote will be positive (recommendation for approval) or negative (recommendation against approval).

To play in the contest, please submit your predictions for all five FDA events using the "Add Comment" button found at the top or bottom of this Web page.

IMPORTANT: All entries must be submitted by 6 am EDT on Monday, June 18.

Good luck!

--Written by Adam Feuerstein in Boston.



>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: [e-mail].

Follow TheStreet on Twitter and become a fan on Facebook.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.